Pulmonx (NASDAQ:LUNG) Issues Earnings Results

Pulmonx (NASDAQ:LUNG) posted its quarterly earnings results on Wednesday. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.12, Zacks reports. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. Pulmonx updated its FY 2025 guidance to EPS.

Pulmonx Stock Down 5.0 %

NASDAQ:LUNG traded down $0.35 during mid-day trading on Wednesday, hitting $6.64. 565,488 shares of the company’s stock traded hands, compared to its average volume of 230,734. The company has a fifty day moving average of $6.42 and a 200 day moving average of $6.74. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. Pulmonx has a twelve month low of $5.46 and a twelve month high of $14.60. The company has a market capitalization of $262.21 million, a P/E ratio of -4.52 and a beta of 0.64.

Insiders Place Their Bets

In related news, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $6.63, for a total value of $132,600.00. Following the completion of the transaction, the director now owns 1,071,974 shares in the company, valued at $7,107,187.62. This trade represents a 1.83 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel David Aaron Lehman sold 5,497 shares of Pulmonx stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $6.19, for a total value of $34,026.43. Following the sale, the general counsel now directly owns 197,851 shares of the company’s stock, valued at approximately $1,224,697.69. This represents a 2.70 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,199 shares of company stock valued at $208,859. 5.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on LUNG shares. Stifel Nicolaus decreased their price objective on Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, October 31st. Citigroup reiterated a “neutral” rating and issued a $7.50 target price (down from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Finally, Wells Fargo & Company lowered their price target on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Pulmonx currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.75.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.